SPHR.F Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Starpharma Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.068 |
52 Week High | AU$0.21 |
52 Week Low | AU$0.068 |
Beta | 0.78 |
11 Month Change | -13.15% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | -92.88% |
5 Year Change | -92.84% |
Change since IPO | -90.29% |
Recent News & Updates
Recent updates
Shareholder Returns
SPHR.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -4.4% | -1.3% | 1.0% |
1Y | n/a | 19.1% | 23.6% |
Return vs Industry: Insufficient data to determine how SPHR.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SPHR.F performed against the US Market.
Price Volatility
SPHR.F volatility | |
---|---|
SPHR.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SPHR.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine SPHR.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 45 | Cheryl Maley | starpharma.com |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers.
Starpharma Holdings Limited Fundamentals Summary
SPHR.F fundamental statistics | |
---|---|
Market cap | US$26.63m |
Earnings (TTM) | -US$5.65m |
Revenue (TTM) | US$7.08m |
3.8x
P/S Ratio-4.7x
P/E RatioIs SPHR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SPHR.F income statement (TTM) | |
---|---|
Revenue | AU$10.52m |
Cost of Revenue | AU$11.68m |
Gross Profit | -AU$1.16m |
Other Expenses | AU$7.24m |
Earnings | -AU$8.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.02 |
Gross Margin | -11.02% |
Net Profit Margin | -79.79% |
Debt/Equity Ratio | 0% |
How did SPHR.F perform over the long term?
See historical performance and comparison